Vitrolife AB Stock
€13.53
Your prediction
Pros and Cons of Vitrolife AB in the next few years
Pros
Cons
Performance of Vitrolife AB vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vitrolife AB | 0.360% | -11.297% | -19.493% | -21.656% | -19.448% | - | - |
| Ekso Bionics Holdings Inc. | -12.080% | -9.664% | -20.488% | -30.285% | -34.690% | -77.118% | - |
| Halyard Health | -0.570% | 0.571% | -2.222% | -36.691% | -12.871% | -52.941% | -52.859% |
| Asensus Surgical Inc. | -1.680% | -2.498% | 0.948% | -62.226% | -23.464% | -84.972% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Vitrolife, a key player in the healthcare equipment and supplies industry, presents financials that initially denote stability and growth potential when observed through various financial statements and ratios. The robustness of their balance sheets over the recent years suggests that the company has been maintaining a sound asset base with consistent growth in stockholder equity. However, a closer and more detailed investigation into their financials is necessary to uncover the intricacies of their performance and potential areas of concern.
Revenue and Profitability Growth: The company's total revenue reveals a positive trend, showing an upward trajectory in recent years. A noticeable aspect is the year-over-year (YOY) quarterly revenue growth which stands at 6.3%. Furthermore, the gross profit TTM (Trailing Twelve Months) is quite substantial at $1.78 billion, underscoring the company's ability to manage its cost of sales effectively and maintain profitable operations.
Solid Asset Base: The balance sheets for the years 2020-2022 reveal a consistently increasing total asset figure, which is a mark of the company's growth and ability to generate value from its assets. The total stockholder equity has also seen significant increment—a signal that the intrinsic value of the company is on the rise.
